Bone Therapeutics, Rigenerand partner on cell therapy process development

By The Science Advisory Board staff writers

January 14, 2021 -- Bone Therapeutics and Rigenerand have formed a cell therapy process development partnership.

Under the collaboration, Bone Therapeutics and Rigenerand will focus on different aspects of product and process development for Bone Therapeutics' therapeutic portfolio. Rigenerand will contribute by improving the processes involved in the development and manufacture of Bone Therapeutics' mesenchymal stem cell-based allogenic differentiated cell therapy products as they advance to the clinic.

The first collaboration between the companies will focus on augmented professional bone-forming cells. There is also the potential for Bone Therapeutics to broaden its therapeutic targets and explore new mechanisms of action with potential gene modifications for its therapeutic portfolio.

In addition, Bone Therapeutics has selected Rigenerand as a partner for a good manufacturing practice manufacturing facility in Italy. The facility hosts development processes for advanced therapy medicinal products including somatic, tissue-engineered, and gene therapy processes.

Financial details of the collaboration were not disclosed.

Bone Therapeutics acquires Catalent cell therapy manufacturer
Catalent Pharma Solutions has completed the acquisition of Bone Therapeutics' manufacturing subsidiary, Skeletal Cell Therapy Support.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter